24 Hour IOP Lowering Efficacy of AL-3789

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00643669

Enrollment

Registered

2008-03-26

Start date

2008-02-29

Completion date

Unknown

Last updated

2012-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open-angle Glaucoma

Brief summary

The objective of this study was to describe the intraocular pressure-lowering efficacy of AL-3789 over a 24-hour period in patients with open-angle glaucoma compared to an untreated control. Patients received one treatment of AL-3789. Twenty-eight days after treatment, IOP was measured every 4 hours, beginning at 8 AM for 24 hours.

Interventions

DRUGAL-3789 Sterile Suspension

Single administration by anterior juxtascleral depot

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of open-angle glaucoma and treated for at least 30 days prior to Screening Visit with a topical prostaglandin analog as monotherapy. * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Pregnant, intend to become pregnant, breastfeeding. * Difference in IOP greater than 3 mm Hg between eyes at Screening Visit. * Any form of glaucoma other than open-angle glaucoma. * Other protocol-defined

Design outcomes

Primary

Measure	Time frame
Mean Intraocular Pressure (IOP)	Day 28, Up to 24 hours

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026